Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 101 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Omalizumab in the Treatment of Peanut Allergy

NCT00949078
Conditions
Food Allergy, Peanut Allergy
Interventions
omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Allergic Asthma
Interventions
Levocetirizine Dihydrochloride, Placebo
Drug
Lead sponsor
Bridgette Jones
Other
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Osteoarthritis of the Knee
Interventions
Apitox, purified honeybee toxin, lyophilized in saline, histamine
Biological
Lead sponsor
Apimeds, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Gulf Shores, Alabama • Tucson, Arizona • Garden Grove, California + 11 more
Completed Phase 2 Interventional Results available

Randomized Trial for Mixed Acute Rejection

NCT00771875
Conditions
Graft Rejection
Interventions
Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib, Acetaminophen, Antihistamine, Methylprednisolone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Otitis Media
Interventions
Antihistamine, Corticosteroid
Drug
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
2 Months to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Oakland, California • Roseville, California • San Francisco, California + 13 more
Conditions
Allergic Asthma, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Phase 2 Interventional Results available

Psilocybin-facilitated Treatment for Cocaine Use

NCT02037126
Conditions
Cocaine-Related Disorders
Interventions
Psilocybin, Diphenhydramine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Normal Non-fluency
Interventions
Olanzapine
Drug
Lead sponsor
Michael Rickels
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more
Conditions
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Conditions
Schizophrenia
Interventions
GSK239512, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Garden Grove, California • Los Angeles, California • National City, California + 11 more
Conditions
Glycogen Storage Disease Type III
Interventions
UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker
Biological · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more
Conditions
Multiple Sclerosis
Interventions
Carbidopa, L-Histidine
Drug · Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Conditions
Graft vs. Host Disease
Interventions
Obinutuzumab, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Conditions
Hay Fever, Hypersensitivity, Allergy, Rhinitis
Interventions
omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Iowa City, Iowa • Omaha, Nebraska • Madison, Wisconsin
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383
Conditions
Multiple Sclerosis
Interventions
L-Histidine, Placebo, Lodosyn
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
JOB's Syndrome, Hyper-IgE Recurrent Infection Syndrome, Immune Deficiency
Interventions
Ranitidine, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Red Man Syndrome
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Months to 21 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Leukemia
Interventions
aldesleukin, histamine dihydrochloride
Biological · Drug
Lead sponsor
Maxim Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 26 more
Conditions
Atopic Dermatitis
Interventions
LEO 152020 tablet, LEO 152020 placebo tablet
Drug
Lead sponsor
JW Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Beverly Hills, California • Los Angeles, California • San Diego, California + 3 more